Severe asthma: what is new in the new millennium.
Sign Up to like & getrecommendations! Published in 2020 at "Current Opinion in Allergy and Clinical Immunology"
DOI: 10.1097/aci.0000000000000623
Abstract: PURPOSE OF REVIEW Severe asthma remains a debilitating disease and a challenge for the clinicians. Novel therapies have been introduced and have greatly improved asthma control and more are under development or in clinical studies.… read more here.
Keywords: severe asthma; asthma new; asthma; new new ... See more keywords
AB0470 EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) - ONE-YEAR FOLLOW-UP STUDY USING MEPOLIZUMAB ANTI-IL5 THERAPY AS A STEROID SPARING THERAPEUTIC APPROACH
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.6555
Abstract: Background: EGPA is a small vessel vasculitis characterised by the presence of tissue eosinophilia, necrotising vasculitis and granulomatous inflammation1. Typically, a prodromal asthmatic phase, leads to an eosinophilic stage, which can evolve to include the… read more here.
Keywords: therapy; none declared; study; il5 therapy ... See more keywords
Anti-IL5 Therapies for Severe Eosinophilic Asthma: Literature Review and Practical Insights
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Asthma and Allergy"
DOI: 10.2147/jaa.s258594
Abstract: Abstract Severe refractory asthma (SRA) still has a high economic and social impact, including a reduction in quality of life (QoL), productivity, a greater risk of exacerbations and emergency department (ED) visits. Another major issue… read more here.
Keywords: eosinophilic asthma; biological drugs; review; therapies severe ... See more keywords